Skip to content
Bored Studies
RecruitingPhase 2

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

Draig Therapeutics Ltd · NCT07300969

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
300
US sites recruiting
20
Study start
December 16, 2025
Record last updated
October 8, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.

Being studied: DT-101; DT-101; Placebo

Conditions: Major Depressive Disorder (MDD)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • The participant is able to read, understand and communicate in the local language used at the study site, and is willing to provide written informed consent
  • Male or female (assigned at birth, inclusive of all gender identities) participant must be 18 to 75 years of age, inclusive at the time of signing the informed consent.
  • Has recurrent depression (defined as at least one prior episode excluding the current one), as diagnosed by DSM 5-TR (Diagnostic and Statistical Manual of Mental Disorders, 2022).

Exclusion Criteria

  • Pregnant or breastfeeding or plans to become pregnant during the study.
  • Unstable medical condition or unstable chronic disease.
  • Significant neurological abnormality.
  • History of moderate or severe alcohol or drug use disorder as per DSM-5-TR in the 6 months prior to Screening.
  • History of seizure.
  • In the investigator's opinion, the participant is not capable of adhering to the protocol requirements.

Recruiting US locations

  • Draig Clinical Site

    Bentonville, AR 72712

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Little Rock, AR 72211

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Oceanside, CA 92056

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    San Diego, CA 92103

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Torrance, CA 90502

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Miami, FL 33166

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Orlando, FL 32803

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Atlanta, GA 30331

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Decatur, GA 30030

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Gaithersburg, MD 20877

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Watertown, MA 02472

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Flowood, MS 39232

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Las Vegas, NV 89102

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Marlton, NJ 08009

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    New York, NY 10312

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Austin, TX 78737

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Austin, TX 78754

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    DeSoto, TX 75115

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Richardson, TX 75243

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

  • Draig Clinical Site

    Bellevue, WA 98004

    Site contact: Draig Clinical Site · +44(0)2920028450 · info@draigtherapeutics.com

Study contacts (from the official record)

  • Chief Medical Officer · +44(0)2920028450 · info@draigtherapeutics.com
All mental health studies in Arkansas →
A Study to Evaluate the Effectiveness of DT-101 in Patients With… (NCT07300969) | Bored Studies